trail neutralizing antibody Search Results


anti–mouse trail mab  (Becton Dickinson)
90
Becton Dickinson anti–mouse trail mab
Correlation between IFN-γ activity and NK cell <t>TRAIL</t> expression. (A) Serum was collected from untreated (▪) or anti-asGM1–treated BALB/c WT mice (•) or BALB/c CD1d −/ − mice (▴) as indicated, and mouse IFN-γ measured by a specific ELISA. (B) Sera were also taken 24 h after treatment as per the Renca tumor therapy regime (above) from IL-12– (black bars), α-GalCer– (white bars), or IL-2 (striped bars)–treated mice. For A and B, data represent the mean ± SE (ng/ml) of duplicate samples from three different mice. The serum of all untreated mice contained <50 pg/ml of IFN-γ. (C) MNCs from the liver and spleen were isolated from PBS- or vehicle-treated (control) BALB/c IFN-γ −/ − mice at 24 h after the treatment with IL-12 (500 U intraperitoneally on days −5, −4, −3, −2, and −1) or α-GalCer (α-GC; 2 μg intraperitoneally on days −8, −4, and 0), or at 3 h after the treatment with IFN-γ (50,000 U intraperitoneally). These cells were stained with biotin-conjugated anti-TRAIL mAb followed by PE-conjugated streptavidin, FITC-conjugated anti-DX5 mAb, and Cy-Chrome–conjugated anti-CD3 mAb. Expression of TRAIL was analyzed on electronically gated CD3 − DX-5 + (NK) cells by flow cytometry. Bold lines indicate staining with anti-TRAIL mAb and plain lines indicate staining with isotype-matched control IgG2a.
Anti–Mouse Trail Mab, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti–mouse trail mab/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti–mouse trail mab - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
human trail neutralizing monoclonal antibody (2e5  (Enzo Biochem)
90
Enzo Biochem human trail neutralizing monoclonal antibody (2e5
Correlation between IFN-γ activity and NK cell <t>TRAIL</t> expression. (A) Serum was collected from untreated (▪) or anti-asGM1–treated BALB/c WT mice (•) or BALB/c CD1d −/ − mice (▴) as indicated, and mouse IFN-γ measured by a specific ELISA. (B) Sera were also taken 24 h after treatment as per the Renca tumor therapy regime (above) from IL-12– (black bars), α-GalCer– (white bars), or IL-2 (striped bars)–treated mice. For A and B, data represent the mean ± SE (ng/ml) of duplicate samples from three different mice. The serum of all untreated mice contained <50 pg/ml of IFN-γ. (C) MNCs from the liver and spleen were isolated from PBS- or vehicle-treated (control) BALB/c IFN-γ −/ − mice at 24 h after the treatment with IL-12 (500 U intraperitoneally on days −5, −4, −3, −2, and −1) or α-GalCer (α-GC; 2 μg intraperitoneally on days −8, −4, and 0), or at 3 h after the treatment with IFN-γ (50,000 U intraperitoneally). These cells were stained with biotin-conjugated anti-TRAIL mAb followed by PE-conjugated streptavidin, FITC-conjugated anti-DX5 mAb, and Cy-Chrome–conjugated anti-CD3 mAb. Expression of TRAIL was analyzed on electronically gated CD3 − DX-5 + (NK) cells by flow cytometry. Bold lines indicate staining with anti-TRAIL mAb and plain lines indicate staining with isotype-matched control IgG2a.
Human Trail Neutralizing Monoclonal Antibody (2e5, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human trail neutralizing monoclonal antibody (2e5/product/Enzo Biochem
Average 90 stars, based on 1 article reviews
human trail neutralizing monoclonal antibody (2e5 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Correlation between IFN-γ activity and NK cell TRAIL expression. (A) Serum was collected from untreated (▪) or anti-asGM1–treated BALB/c WT mice (•) or BALB/c CD1d −/ − mice (▴) as indicated, and mouse IFN-γ measured by a specific ELISA. (B) Sera were also taken 24 h after treatment as per the Renca tumor therapy regime (above) from IL-12– (black bars), α-GalCer– (white bars), or IL-2 (striped bars)–treated mice. For A and B, data represent the mean ± SE (ng/ml) of duplicate samples from three different mice. The serum of all untreated mice contained <50 pg/ml of IFN-γ. (C) MNCs from the liver and spleen were isolated from PBS- or vehicle-treated (control) BALB/c IFN-γ −/ − mice at 24 h after the treatment with IL-12 (500 U intraperitoneally on days −5, −4, −3, −2, and −1) or α-GalCer (α-GC; 2 μg intraperitoneally on days −8, −4, and 0), or at 3 h after the treatment with IFN-γ (50,000 U intraperitoneally). These cells were stained with biotin-conjugated anti-TRAIL mAb followed by PE-conjugated streptavidin, FITC-conjugated anti-DX5 mAb, and Cy-Chrome–conjugated anti-CD3 mAb. Expression of TRAIL was analyzed on electronically gated CD3 − DX-5 + (NK) cells by flow cytometry. Bold lines indicate staining with anti-TRAIL mAb and plain lines indicate staining with isotype-matched control IgG2a.

Journal: The Journal of Experimental Medicine

Article Title: Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis

doi:

Figure Lengend Snippet: Correlation between IFN-γ activity and NK cell TRAIL expression. (A) Serum was collected from untreated (▪) or anti-asGM1–treated BALB/c WT mice (•) or BALB/c CD1d −/ − mice (▴) as indicated, and mouse IFN-γ measured by a specific ELISA. (B) Sera were also taken 24 h after treatment as per the Renca tumor therapy regime (above) from IL-12– (black bars), α-GalCer– (white bars), or IL-2 (striped bars)–treated mice. For A and B, data represent the mean ± SE (ng/ml) of duplicate samples from three different mice. The serum of all untreated mice contained <50 pg/ml of IFN-γ. (C) MNCs from the liver and spleen were isolated from PBS- or vehicle-treated (control) BALB/c IFN-γ −/ − mice at 24 h after the treatment with IL-12 (500 U intraperitoneally on days −5, −4, −3, −2, and −1) or α-GalCer (α-GC; 2 μg intraperitoneally on days −8, −4, and 0), or at 3 h after the treatment with IFN-γ (50,000 U intraperitoneally). These cells were stained with biotin-conjugated anti-TRAIL mAb followed by PE-conjugated streptavidin, FITC-conjugated anti-DX5 mAb, and Cy-Chrome–conjugated anti-CD3 mAb. Expression of TRAIL was analyzed on electronically gated CD3 − DX-5 + (NK) cells by flow cytometry. Bold lines indicate staining with anti-TRAIL mAb and plain lines indicate staining with isotype-matched control IgG2a.

Article Snippet: All these reagents, except anti–mouse TRAIL mAb, were obtained from BD PharMingen.

Techniques: Activity Assay, Expressing, Mouse Assay, Enzyme-linked Immunosorbent Assay, Isolation, Staining, Flow Cytometry